Equities

Concord Biotech Ltd

CONCORDBIO:NSI

Concord Biotech Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,019.30
  • Today's Change19.30 / 0.96%
  • Shares traded74.97k
  • 1 Year change+59.75%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 10:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic process and finished formulations. The Company’s offerings span both bio-pharmaceutical APIs and formulations across therapeutic areas like immunosuppressants oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in anti-bacterial, anti-fungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, Teicoplanin, Polymyxin B Sulfate, Fidaxomicin, Anidulafungin. Its API products under development include Daptomycin, Epirubicin, Idarubicin, and Pirarubicin.

  • Revenue in INR (TTM)10.86bn
  • Net income in INR3.28bn
  • Incorporated1984
  • Employees1.38k
  • Location
    Concord Biotech Ltd10th FloorNr. Prahladnagar Garden, 100ft RoadAHMEDABAD 380015IndiaIND
  • Phone+91 7 968138700
  • Fax+91 2 714222504
  • Websitehttp://www.concordbiotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Strides Pharma Science Ltd44.10bn1.77bn138.27bn3.07k78.246.0837.203.1419.2225.15479.84247.160.71551.503.5714,389,290.002.79-1.685.43-2.9760.1951.393.91-3.360.63551.520.5103--9.8313.2143.57---18.52-3.58
Sanofi India Ltd21.92bn3.60bn139.95bn2.17k38.86--35.226.38156.36199.60951.86--------10,083,720.00--22.42--30.2153.9455.5216.4321.03--348.40--135.492.920.573-2.859.64-10.3414.73
Marksans Pharma Ltd23.79bn3.47bn140.10bn2.00k40.356.1432.555.897.667.6652.5350.340.91051.654.7511,893,400.0013.3014.6215.7818.5255.3250.5214.6114.032.9731.250.07926.1717.5616.8417.8032.6273.8664.38
Caplin Point Laboratories Ltd18.31bn4.94bn147.68bn859.0030.025.8126.388.0764.7364.73240.10334.540.68612.283.4021,312,920.0018.6219.8321.3622.8258.7253.3827.1425.395.07932.860.00099.0615.5021.1721.4820.9517.4717.84
Astrazeneca Pharma India Ltd14.85bn819.20m157.64bn940.00192.4523.20153.6210.6232.7632.76593.93271.741.272.5210.6315,792,680.006.9911.7811.4419.6244.8854.645.5210.271.44134.820.024625.6229.1712.2162.6624.29-10.46--
Jubilant Pharmova Ltd69.20bn5.93bn179.04bn995.0030.243.0118.522.5937.3837.38436.41375.040.59341.758.1569,544,720.005.052.966.013.5568.5068.478.515.131.202.510.34224.736.70-5.95226.43-33.086.482.13
Eris Lifesciences Ltd24.98bn3.48bn186.04bn3.08k53.456.7129.877.4525.5725.57183.35203.740.45852.905.968,110,753.006.7313.428.3916.8077.0379.9814.6924.960.85993.410.4626--19.2315.392.576.1527.72--
Neuland Laboratories Ltd.15.28bn2.80bn189.47bn1.65k67.7513.6555.1412.40217.98217.981,191.201,081.520.8472.144.859,273,565.0015.509.2520.0312.7152.1447.8118.3011.991.4031.560.07287.1330.8418.5183.5178.7617.8863.45
Wockhardt Ltd29.49bn-2.88bn190.86bn2.39k--5.31--6.47-19.85-19.85201.29221.320.3931.874.1912,318,300.00-3.93-4.56-6.33-8.2959.1055.26-10.00-12.700.56770.2470.3869--5.55-4.7317.17---4.71--
Alembic Pharmaceuticals Ltd63.57bn6.47bn204.00bn14.86k31.564.1722.063.2132.8832.88323.14248.680.9290.93665.434,278,678.009.4510.7213.3214.2573.8465.9810.1712.470.805712.620.179128.2910.199.6280.071.05-15.5914.87
Concord Biotech Ltd10.86bn3.28bn208.31bn1.38k53.7613.1054.5819.1937.0437.04114.79152.020.6551.113.557,884,886.0019.78--21.82--76.00--30.20--4.83194.730.0022--19.20--28.33------
Pfizer Ltd22.38bn6.18bn234.75bn1.72k37.996.2634.5810.49135.06135.06489.19819.900.52881.8311.1613,004,360.0014.6014.2217.0517.7165.0061.3727.6124.054.3046.210.026782.67-9.551.05-11.645.1433.359.24
Emcure Pharmaceuticals Ltd72.56bn5.67bn242.76bn11.15k42.275.8925.283.3530.3730.37389.63217.790.9781.803.966,510,068.008.027.1413.5513.9361.1159.298.207.810.95495.250.21650.0011.237.14-6.3621.35-5.93--
Natco Pharma Ltd.45.61bn19.45bn246.23bn4.02k12.663.4411.545.40108.58108.58254.65399.190.62910.89283.5711,356,080.0026.8212.3330.8514.2585.4773.0542.6325.164.19108.700.028318.9647.7213.8194.0916.59-4.7114.87
Laurus Labs Ltd50.53bn1.31bn263.73bn6.01k201.066.3848.375.222.432.4393.7076.700.6021.183.068,412,186.001.5510.132.5216.4753.4447.632.5812.830.58181.810.402313.00-16.5517.07-79.6811.3621.6821.67
J B Chemicals and Pharmaceuticals Ltd37.11bn6.11bn264.35bn5.31k44.278.2334.407.1238.4538.45233.33206.820.94812.594.856,987,882.0015.6115.7718.6218.8966.2661.1816.4716.062.2027.530.030333.0810.6316.2234.8423.3640.1537.42
Data as of Nov 22 2024. Currency figures normalised to Concord Biotech Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

12.05%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 31 Mar 20242.26m2.16%
The Vanguard Group, Inc.as of 06 Nov 20242.14m2.05%
Max Life Insurance Co. Ltd.as of 31 Mar 20241.59m1.52%
Tata AIA Life Insurance Co. Ltd.as of 31 Oct 20241.24m1.18%
HSBC Global Asset Management (Hong Kong) Ltd.as of 31 Aug 20241.21m1.16%
Invesco Asset Management (India) Pvt Ltd.as of 31 Oct 20241.11m1.06%
HSBC Asset Management (India) Pvt Ltd.as of 31 Oct 20241.07m1.02%
Edelweiss Asset Management Ltd.as of 31 Oct 2024762.85k0.73%
Baroda BNP Paribas Asset Management India Pvt Ltd.as of 31 Oct 2024650.53k0.62%
DSP Asset Managers Pvt. Ltd.as of 31 Oct 2024583.97k0.56%
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.